Synthace is a biotechnology software company that develops cloud-based platforms for automating and optimizing laboratory experiments. The company's flagship product, Antha, enables researchers to design, simulate, and execute complex biological experiments using automated lab equipment, helping to accelerate research and development in life sciences.
Founded to address inefficiencies in laboratory workflows, Synthace serves pharmaceutical companies, biotech firms, and research institutions looking to scale their experimental capabilities. The platform integrates with various lab automation hardware and provides a programming language specifically designed for biological protocols. The company has raised funding from notable investors and continues to expand its presence in the synthetic biology and lab automation markets, positioning itself as a key enabler of the digital transformation in life sciences research.
Synthace has received investment from 2 venture capital firms.
Cloud-based platform that automates and optimizes laboratory experiments for biotechnology and pharmaceutical research.
Synthace has received investment from Air Street Capital, Crane Venture Partners. These venture capital firms and investors provide both capital and strategic support.
Synthace operates in the Biotech sector. Cloud-based platform that automates and optimizes laboratory experiments for biotechnology and pharmaceutical research.
